Board Meeting3 Aug 2026, 03:49 pm
GSK Pharma Board Approves Q1 2026 Un-audited Financial Results
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026, along with the Limited Review Report. Key management changes were also noted: Mr. Subesh Williams stepped down as Non-Executive Director, Ms. Karine J F Natland was appointed as Non-Executive Director, and Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. The meeting commenced at 1:00 PM and concluded at 3:35 PM.
Key Highlights
- Board approved Q1 2026 un-audited standalone and consolidated financial results.
- Mr. Subesh Williams resigned as Non-Executive Director.
- Ms. Karine J F Natland appointed as Non-Executive Director.
- Mr. Bhushan Akshikar re-appointed as Managing Director for two years.
- Financial results for the quarter ended June 30, 2026, were declared.
Price Impact
More from GLAXO